Brown & Brown, Inc. (BRO)
NYSE: BRO · Real-Time Price · USD
91.80
+0.13 (0.14%)
Aug 6, 2025, 4:00 PM - Market closed
Achilles Therapeutics Stock Forecast
Stock Price Forecast
The 12 analysts that cover Achilles Therapeutics stock have a consensus rating of "Buy" and an average price target of $115.08, which forecasts a 25.36% increase in the stock price over the next year. The lowest target is $87 and the highest is $130.
Price Target: $115.08 (+25.36%)
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for Achilles Therapeutics stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Mar '25 | Apr '25 | May '25 | Jun '25 | Jul '25 | Aug '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 2 | 2 | 1 | 2 | 2 |
| Buy | 3 | 3 | 3 | 4 | 3 | 4 |
| Hold | 6 | 6 | 7 | 6 | 5 | 5 |
| Sell | 1 | 1 | 1 | 1 | 1 | 1 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 12 | 12 | 13 | 12 | 11 | 12 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Raymond James | Raymond James | Buy Reiterates $125 → $120 | Buy | Reiterates | $125 → $120 | +30.72% | Aug 4, 2025 |
| Keefe, Bruyette & Woods | Keefe, Bruyette & Woods | Sell Maintains $104 → $87 | Sell | Maintains | $104 → $87 | -5.23% | Jul 31, 2025 |
| BMO Capital | BMO Capital | Buy Maintains $122 → $106 | Buy | Maintains | $122 → $106 | +15.47% | Jul 30, 2025 |
| Wells Fargo | Wells Fargo | Buy Maintains $127 → $104 | Buy | Maintains | $127 → $104 | +13.29% | Jul 30, 2025 |
| B of A Securities | B of A Securities | Hold → Strong Buy Upgrades $126 → $130 | Hold → Strong Buy | Upgrades | $126 → $130 | +41.61% | Jul 30, 2025 |
Financial Forecast
Revenue This Year
5.61B
from 4.71B
Increased by 19.12%
Revenue Next Year
6.81B
from 5.61B
Increased by 21.27%
EPS This Year
4.21
from 3.46
Increased by 21.54%
EPS Next Year
4.75
from 4.21
Increased by 12.96%
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 6.2B | 7.8B | 8.5B | ||
| Avg | 5.6B | 6.8B | 7.4B | ||
| Low | 5.1B | 5.4B | 5.8B |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 31.1% | 39.7% | 24.9% | ||
| Avg | 19.1% | 21.3% | 9.1% | ||
| Low | 7.4% | -3.5% | -15.5% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | 4.49 | 5.24 | 6.07 |
| Avg | 4.21 | 4.75 | 5.24 |
| Low | 3.87 | 4.19 | 4.55 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | 29.9% | 24.6% | 27.8% |
| Avg | 21.5% | 13.0% | 10.3% |
| Low | 11.8% | -0.3% | -4.3% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.